A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis
Tóm tắt
Azelastine has been shown to be effective against seasonal allergic rhinitis (SAR). The Environmental Exposure Unit (EEU) is a validated model of experimental SAR. The objective of this double-blind, four-way crossover study was to evaluate the onset of action of azelastine nasal spray, versus the oral antihistamines loratadine 10 mg and cetirizine 10 mg in the relief of the symptoms of SAR. 70 participants, aged 18-65, were randomized to receive azelastine nasal spray, cetirizine, loratadine, or placebo after controlled ragweed pollen exposure in the EEU. Symptoms were evaluated using the total nasal symptom score (TNSS). The primary efficacy parameter was the onset of action as measured by the change from baseline in TNSS. Azelastine displayed a statistically significant improvement in TNSS compared with placebo at all time points from 15 minutes through 6 hours post dose. Azelastine, cetirizine, and loratadine reduced TNSS compared to placebo with an onset of action of 15 (p < 0.001), 60 (p = 0.015), and 75 (p = 0.034) minutes, respectively. The overall assessment of efficacy was rated as good or very good by 46% of the participants for azelastine, 51% of the participants for cetirizine, and 30% of the participants for loratadine compared to 18% of the participants for placebo. Azelastine’s onset of action for symptom relief was faster than that of cetirizine and loratadine. The overall participant satisfaction in treatment with azelastine is comparable to cetirizine and statistically superior to loratadine. These results suggest that azelastine may be preferential to oral antihistamines for the rapid relief of SAR symptoms.
Tài liệu tham khảo
Horak F, Zieglmayer UP: Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis. Expert Rev Clin Immunol. 2009, 5: 659-669. 10.1586/eci.09.38.
van Cauwenberge P, Bachert C, Passalacqua G: Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000, 55: 116-134. 10.1034/j.1398-9995.2000.00526.x.
Leung AK, Hon KL: Seasonal allergic rhinitis. Recent Pat Inflamm Allergy Drug Discov. 2008, 2: 175-185. 10.2174/187221308786241965.
Slack RJ, Hart AD, Luttmann MA, Clark KL, Begg M: In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine. Eur J Pharmacol. 2011, 670: 586-592. 10.1016/j.ejphar.2011.09.017.
Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H: Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009, 30: 628-633. 10.2500/aap.2009.30.3296.
van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H: Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009, 30: 512-518. 10.2500/aap.2009.30.3284.
Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008, 4: 1009-1022.
Lumry W, Prenner B, Corren J, Wheeler W: Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Ann Allergy Asthma Immunol. 2007, 99: 267-272. 10.1016/S1081-1206(10)60663-1.
Bernstein JA, Prenner B, Ferguson BJ, Portnoy J, Wheeler WJ, Sacks HJ: Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. Am J Rhinol Allergy. 2009, 23: 512-517. 10.2500/ajra.2009.23.3396.
Lieberman P: Intranasal antihistamines for allergic rhinitis: mechanism of action. Allergy Asthma Proc. 2009, 30: 345-348. 10.2500/aap.2009.30.3263.
Kaliner MA: Azelastine and olopatadine in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2009, 103: 373-380. 10.1016/S1081-1206(10)60355-9.
Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007, 23: 2441-2452. 10.1185/030079907X226302.
Hernandez-Trujillo V: Antihistamines treatment for allergic rhinitis: different routes, different mechanisms?. Allergy Asthma Proc. 2009, 30: 584-588. 10.2500/aap.2009.30.3289.
Day JH, Briscoe MP: Environmental exposure unit: a system to test anti-allergic treatment. Ann Allergy Asthma Immunol. 1999, 83: 83-89. 10.1016/S1081-1206(10)62616-6. quiz 89-93
Day JH, Ellis AK, Rafeiro E, Ratz JD, Briscoe MP: Experimental models for the evaluation of treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2006, 96: 263-277. 10.1016/S1081-1206(10)61235-5.
Ellis AK: Why use an environmental exposure unit to study allergic rhinitis?. Asthma Allergies Children. 2012, online guest editorial
Day JH, Briscoe MP, Rafeiro E, Hewlett D, Chapman D, Kramer B: Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2004, 25: 59-68.
Day JH, Briscoe MP, Rafeiro E, Ratz JD: Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract. 2004, 58: 109-118. 10.1111/j.1368-5031.2004.0117.x.
Day JH, Briscoe MP, Rafeiro E: Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit. Allergy Asthma Proc. 2005, 26: 275-282.
Day JH, Briscoe MP, Ratz JD: Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the Environmental Exposure Unit. Allergy Asthma Proc. 2008, 29: 304-312. 10.2500/aap.2008.29.3109.
Day JH, Briscoe MP, Ratz JD, Danzig M, Yao R: Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Ann Allergy Asthma Immunol. 2009, 102: 328-338. 10.1016/S1081-1206(10)60339-0.
Day JH, Briscoe MP, Ratz JD, Ellis AK, Yao R, Danzig M: Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the Environmental Exposure Unit. Allergy Asthma Proc. 2009, 30: 270-276. 10.2500/aap.2009.30.3234.
Ellis AK, Ratz JD, Day AG, Day JH: Factors that affect the allergic rhinitis response to ragweed allergen exposure. Ann Allergy Asthma Immunol. 2010, 104: 293-298. 10.1016/j.anai.2010.01.012.
Astelin® (azelastine hydrochloride) Nasal Spray: [prescribing information]. 2006, Somerset, NJ: MedPointe Healthcare
Horak F, Zieglmayer UP, Zieglmayer R: Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006, 22: 151-157. 10.1185/030079906X80305.
Patel P, D'Andrea C, Sacks HJ: Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007, 21: 499-503. 10.2500/ajr.2007.21.3058.
Hanashiro K, Sunagawa M, Tokeshi Y: Antiallergic drugs, azelastine hydrochloride and epinastine hydrochloride, inhibit ongoing IgE secretion of rat IgE-producing hybridoma FE-3 cells. Eur J Pharmacol. 2006, 547: 174-183. 10.1016/j.ejphar.2006.07.012.
Lieberman P, Kaliner MA, Wheeler WJ: Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr Med Res Opin. 2005, 21: 611-618. 10.1185/030079905X41408.
Day JH, Briscoe M, Widlitz MD: Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998, 101: 638-645. 10.1016/S0091-6749(98)70172-1.
Day JH, Briscoe M, Rafeiro E, Chapman D, Kramer B: Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol. 2001, 87: 474-481. 10.1016/S1081-1206(10)62260-0.
Corren J, Storms W, Bernstein J: Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther. 2005, 27: 543-553. 10.1016/j.clinthera.2005.04.012.
Berger W, Hampel F, Bernstein J, Shah S, Sacks H, Meltzer EO: Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006, 97: 375-381. 10.1016/S1081-1206(10)60804-6.
Berger WE, White MV: Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol. 2003, 91: 205-211. 10.1016/S1081-1206(10)62179-5.